Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) - Trial NCT06155500
Access comprehensive clinical trial information for NCT06155500 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Not yet recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 5 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novartis Pharmaceuticals
Novartis
Timeline & Enrollment
N/A
Nov 27, 2023
Jul 25, 2025
Primary Outcome
Number of participants with delayed adverse events that are suspected to be related to previous OTQ923 therapy
Summary
CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled
 patients who have received treatment with OTQ923 for long-term safety and efficacy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06155500
Non-Device Trial